PharmaCyte Biotech shareholders approve reverse split authority, equity plan increase
At its annual meeting on March 30, 2026, PharmaCyte Biotech stockholders approved five proposals, including authority for the board to effect a reverse stock split at a ratio between 1-for-1.1 and 1-for-100 and a 2,000,000-share increase to the 2022 Equity Incentive Plan. The filing does not say whether the board plans to use the reverse split authority. The meeting also covered director elections, auditor ratification and a non-binding advisory vote on executive pay.
Key points
- Reverse split authority approved: 5,067,304 votes for, 2,280,497 against, 40,056 abstain; the board may split at 1-for-1.1 to 1-for-100 but is not required to.
- Equity plan amended to add 2,000,000 shares: 3,133,280 votes for, 804,435 against, 9,572 abstain.
- All five directors nominated, including Joshua N. Silverman, received between 3,397,282 and 3,574,494 votes for; CBIZ CPAs P.C. was ratified as auditor for the year ending April 30, 2026 with 6,837,442 votes for.
- Quorum of 7,387,861 shares, about 55.08% of shares entitled to vote, was present; the non-binding say-on-pay proposal drew 3,306,883 votes for and 625,080 against.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.